Загрузка...
Unlocking the potential of antibody–drug conjugates for cancer therapy
Nine different antibody–drug conjugates (ADCs) are currently approved as cancer treatments, with dozens more in preclinical and clinical development. The primary goal of ADCs is to improve the therapeutic index of antineoplastic agents by restricting their systemic delivery to cells that express the...
Сохранить в:
| Опубликовано в: : | Nat Rev Clin Oncol |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8287784/ https://ncbi.nlm.nih.gov/pubmed/33558752 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41571-021-00470-8 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|